Difference between revisions of "Elranatamab (Elrexfio)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "BiTE antibodies" to "bispecific T-cell engager antibodies") |
m |
||
| Line 22: | Line 22: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | [[Category:Anti-BCMA | + | [[Category:Anti-BCMA/CD3 bispecific antibodies]] |
| − | |||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
[[Category:REMS program]] | [[Category:REMS program]] | ||
[[Category:FDA approved in 2023]] | [[Category:FDA approved in 2023]] | ||
Revision as of 20:40, 3 October 2023
General information
Class/mechanism from the NCI Drug Dictionary: A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, elranatamab binds to both CD3 on T cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells.
Route: IV
Extravasation: no information
Toxicity management
- REMS website TBA
Diseases for which it is established
History of changes in FDA indication
- 2023-08-14: Granted accelerated approval for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (Based on MagnetisMM-3)
Also known as
- Code names: PF-06863135, RN-613
- Generic name: elranatamab-bcmm
- Brand name: Elrexfio